Stimuli-responsive electrospun nanofibers for drug delivery, cancer therapy, wound dressing, and tissue engineering

Chen, Kai; Li, Yonghui; Li, Youbin; Tan, Yinfeng; Liu, Yingshuo; Pan, Weisan; Tan, Guoxin

doi:10.1186/s12951-023-01987-z

Cited by 52 publications

(17 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular disease (CVD) encompasses various conditions, including coronary artery disease, valvular heart disease, myocarditis, cardiomyopathy, and aortic aneurysm, with each arising after a distinct pathophysiologic process. The heart muscle is composed of electro-active tissues, and the regenerative potential of cardiomyocytes is relatively limited, resulting in a restricted capacity for self-repair [ 125 , 130 ]. Consequently, the challenge of repairing cardiomyocytes has persisted over the years up to the present.…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

“…Consequently, the challenge of repairing cardiomyocytes has persisted over the years up to the present. Recent advances in creating functional heart tissue, however, have accelerated CVD therapy, and electrospun materials provide an effective conductive and inducer scaffold suitable for platforms for myocardial and cardiac endothelial cells [ 125 , 130 ] ( Figure 4 ).…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Electrospun Scaffold Innovations in Cardiovascular Therapy: A Review of Electrospinning in Cardiovascular Disease

Broadwin,

Imarhia,

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. In particular, patients who suffer from ischemic heart disease (IHD) that is not amenable to surgical or percutaneous revascularization techniques have limited treatment options. Furthermore, after revascularization is successfully implemented, there are a number of pathophysiological changes to the myocardium, including but not limited to ischemia-reperfusion injury, necrosis, altered inflammation, tissue remodeling, and dyskinetic wall motion. Electrospinning, a nanofiber scaffold fabrication technique, has recently emerged as an attractive option as a potential therapeutic platform for the treatment of cardiovascular disease. Electrospun scaffolds made of biocompatible materials have the ability to mimic the native extracellular matrix and are compatible with drug delivery. These inherent properties, combined with ease of customization and a low cost of production, have made electrospun scaffolds an active area of research for the treatment of cardiovascular disease. In this review, we aim to discuss the current state of electrospinning from the fundamentals of scaffold creation to the current role of electrospun materials as both bioengineered extracellular matrices and drug delivery vehicles in the treatment of CVD, with a special emphasis on the potential clinical applications in myocardial ischemia.

show abstract

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Exploring Electrospun Scaffold Innovations in Cardiovascular Therapy: A Review of Electrospinning in Cardiovascular Disease

Broadwin,

Imarhia,

et al. 2024

Bioengineering

View full text Add to dashboard Cite

show abstract

“…CRES and PRES are both highly capable of producing ESFs customized for drug delivery applications. Their unique properties, which include high surface-area-to-volume ratio, porosity, and crosslinking capabilities, make them very well- suited for tailoring controlled-release smart drug delivery systems and incorporating bioactive ingredients through applying both in situ and post-crosslinking strategies as promising approaches to novel treatments for various diseases and conditions [ 149 ].…”

Section: Biomedical Application Of Rementioning

confidence: 99%

Overview of Tissue Engineering and Drug Delivery Applications of Reactive Electrospinning and Crosslinking Techniques of Polymeric Nanofibers with Highlights on Their Biocompatibility Testing and Regulatory Aspects

Younes,

Kadavil,

Ismail

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Traditional electrospinning is a promising technique for fabricating nanofibers for tissue engineering and drug delivery applications. The method is highly efficient in producing nanofibers with morphology and porosity similar to the extracellular matrix. Nonetheless, and in many instances, the process has faced several limitations, including weak mechanical strength, large diameter distributions, and scaling-up difficulties of its fabricated electrospun nanofibers. The constraints of the polymer solution’s intrinsic properties are primarily responsible for these limitations. Reactive electrospinning constitutes a novel and modified electrospinning techniques developed to overcome those challenges and improve the properties of the fabricated fibers intended for various biomedical applications. This review mainly addresses reactive electrospinning techniques, a relatively new approach for making in situ or post-crosslinked nanofibers. It provides an overview of and discusses the recent literature about chemical and photoreactive electrospinning, their various techniques, their biomedical applications, and FDA regulatory aspects related to their approval and marketing. Another aspect highlighted in this review is the use of crosslinking and reactive electrospinning techniques to enhance the fabricated nanofibers’ physicochemical and mechanical properties and make them more biocompatible and tailored for advanced intelligent drug delivery and tissue engineering applications.

show abstract

“…With their high surface area-to-volume ratio and interconnected porous structure, nano bers promote cell adhesion, proliferation, and differentiation. These nano brous scaffolds create a three-dimensional environment that supports tissue regeneration and can be utilized for various applications, including skin grafts, bone regeneration, and cartilage repair [9].…”

Section: Introductionmentioning

confidence: 99%

Development and Evaluation of a Novel Nanofibrous Chitosan Dressing with Eugenol and Iodoform for Treating Alveolar Osteitis

Arabi,

Kamali,

Abbaspour

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective: Dry socket or alveolar osteitis is the most common complication following bone exposure. Alveolus, after the dissolution of the blood clot in the tooth socket, is accompanied by severe and persistent pain, bad breath, foul taste in the mouth, or localized lymphadenitis. The treatment of dry socket is based on pain relief to facilitate its healing process. One of the commonly used treatments for dry socket is Alvogyl, which is produced by combining indigenous red fibers from South Asia with active ingredients such as eugenol and iodoform. Since access to these fibers is challenging, finding a suitable alternative for this material is essential. Chitosan is a polymeric substance with remarkable antimicrobial properties and is considered safe for human consumption. On the other hand, the production of nanofibers offers desirable characteristics such as an increased surface-to-volume ratio, which, along with other advantages of chitosan use, such as availability and antimicrobial properties, justifies the necessity of this research. Methods and Materials: Based on the properties of chitosan, iodoform, and eugenol, formulations were prepared, including a drug-free formulation, a formulation containing 0.24% iodoform, 0.02% eugenol, and a formulation containing 0.24% iodoform with 0.02% eugenol, using an electrospinning apparatus to produce nanofibers. The characteristics of the polymeric solution, such as viscosity, pH, and electrical conductivity, were examined. The diameter, morphology, and diameter distribution of the nanofibers were investigated using SEM. XRD, DSC, and FT-IR tests were conducted to assess the crystalline properties and interaction of the materials. Drug delivery features, including tensile strength, drug loading, drug release profile, as well as cellular toxicity and minimum inhibitory concentration (MIC) of the nanofiber membrane, were evaluated. Results: Nanofibers were successfully prepared using the electrospinning method, with average fiber diameters of 64 ± 335 nm, 80 ± 360 nm, 97 ± 355 nm, and 59 ± 214 nm for drug-free fibers, fibers containing 0.24% iodoform, 0.02% eugenol, and fibers containing 0.24% iodoform with 0.02% eugenol, respectively. The addition of iodoform and eugenol to the polymer increased the electrical conductivity of the solution and the fibers but decreased the pH and tensile strength. The desired drug loading percentage was achieved for drug-free fibers and fibers containing 0.24% iodoform, 0.02% eugenol, and fibers containing 0.24% iodoform with 0.02% eugenol. FT-IR, DSC, and XRD analyses confirmed the absence of interactions between the drug and excipients in the polymeric membrane. According to the cellular toxicity tests conducted, none of the nanofibers exhibited cytotoxicity against fibroblast cells. Conclusion: Based on the conducted investigations, it can be concluded that iodoform and eugenol can be successfully loaded into chitosan and polyethylene oxide nanofibers. The obtained fibers possess mechanical strength and controlled drug release profiles, making them suitable for dry socket dressings, which should be further evaluated in in vivo tests.

show abstract

Stimuli-responsive electrospun nanofibers for drug delivery, cancer therapy, wound dressing, and tissue engineering

Cited by 52 publications

References 142 publications

Exploring Electrospun Scaffold Innovations in Cardiovascular Therapy: A Review of Electrospinning in Cardiovascular Disease

Exploring Electrospun Scaffold Innovations in Cardiovascular Therapy: A Review of Electrospinning in Cardiovascular Disease

Overview of Tissue Engineering and Drug Delivery Applications of Reactive Electrospinning and Crosslinking Techniques of Polymeric Nanofibers with Highlights on Their Biocompatibility Testing and Regulatory Aspects

Development and Evaluation of a Novel Nanofibrous Chitosan Dressing with Eugenol and Iodoform for Treating Alveolar Osteitis

Contact Info

Product

Resources

About